Clinical Trial Update: The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates the safety and preliminary efficacy of CART-19 autologous CAR-T cells in patients with relapsed or refractory CD19-positive B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CART-19 cells (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: B Cell Lymphoma | Phase 1 | Status: UNKNOWN